AstraZeneca#39;s Dapagliflozin gets DCGI nod for treatment of heart failure patients

AstraZeneca#39;s Dapagliflozin gets DCGI nod for treatment of heart failure patients
AstraZeneca#39;s Dapagliflozin gets DCGI nod for treatment of heart failure patients The company has received import and market permission from DCGI in Form CT-20 (Marketing Authorisation- Additional Indication).